INTRODUCTION
For many years, various chemotherapeutic measures have been employed in the treatment of animal brucellosis, but the results have not been entirely satisfactory. For bovine brucellosis several chemical antimicrobials, minerals, trace elements and vitamins have been tried unsuccessfully (7, 8, 10, 11, 14, 16, 20) . In addition, the Animal Production and Health Section, National Agriculture and Water Research Centre, Ministry of Agriculture and Water, P.O. Box 17285, Riyadh 11484, Saudi Arabia. use of penicillin or sulfonamides failed to cause cessation of the shedding oí Brucella abortus from the udders of infected cows (2, 4, 9, 28) . However, aureomycin, terramycin, streptomycin (ST) or tetracyclines administered in cows infected with B. abortus resulted in the reduction of abortions (18, 19, 26) . Moreover, the recent use of Oxytetracycline (OTC), long-acting (LA)-OTC with or without accompanying injection of ST caused disappearance of the symptoms of bovine brucellosis and reduction in the shedding of B. abortus in udder secretions. However, these treatments were not successful in curing all infected cows (5, 13, 21, 22, 23) .
In sheep, a limited trial has been performed, in which nine sheep infected experimentally with B. abortus were injected daily for 6 days with 1 g Chlortetracycline, then 20 days later with 1.4 g daily for 3 days (together with immune serum). Only one sheep was found to be bacteriologically positive at slaughter 46 days after infection (24) . The treatment regimens in previous trials had involved small doses and few injections of the antibiotics used. In 1989, Radwan and colleagues (25) carried out a long-term treatment trial using different doses of OTC alone or in combination with ST on 118 sheep naturally infected with B. melitensis.
Groups of infected Najdi sheep were given 250, 500 or 1,000 mg OTC daily for 6 weeks by the intraperitoneal (i.p.) route. In the respective groups 52%, 69% and 100% of the sheep were found to the Brucella-free at the end of the trial. Furthermore, the treatment with OTC (250 mg i.p. daily for 6 weeks) combined with ST (1 g i.m. daily for 3 weeks) showed a synergistic effect and increased the percentage of Brucella-free sheep to 82%. In addition, when eight Najdi sheep were inoculated with LA-OTC (1,000 mg i.m. every 3 days for 6 weeks) six animals were Brucella-free at necropsy. Unfortunately, the majority of treated sheep developed subcutaneous sterile abscesses in the flank at the site of repeated i.p. inoculation with OTC. Other investigators (17) reported serious local reactions in cows repeatedly inoculated i.p. with tetracycline.
The purpose of this study was to evaluate the efficacy of various therapeutic regimens using OTC or LA-OTC combined with ST in eliminating B. melitensis from naturally-infected sheep and goats. The study was directed towards obtaining a therapeutic regimen which is practical, effective, without side-effects and relatively inexpensive, to make treatment of infected sheep and goats with superior genes a viable alternative to slaughter.
MATERIALS AND METHODS

Animals
Only sheep and goats which proved to be brucellosis positive both serologically and bacteriologically were selected in order to obtain a more conclusive evaluation. The selected animals had already aborted or lambed two to six months before initiation of the treatment regimens. The study was carried out on 240 sheep of pure Najdi and Naimi breeds (161 and 79 ewes respectively) and 240 goats of pure Syrian, Masry and Balady breeds (132, 51 and 57 respectively). All animals were between three and five years old and weighed between 40 and 50 kg. The infected animals were donated by several breeding farms in Al-Kharj, Dirab, Dawadmi, Haradh, Heremla, Mozahmia, Riyadh and Sahna in Saudi Arabia. The animals were randomly divided into six treatment groups (the distribution of the sheep and goat breeds is shown in Table I ) and one control group. The non-treated control group included 20 sheep (10 Najdi and 10 Naimi ewes) and 20 goats (10 Syrian, 5 Masry and 5 Balady). The control animals were kept without mating to avoid further spread of infection. The treated and control groups were each housed in isolation from other animals.
Immediately after completion of the treatment regimens (Table I) , the treated ewes and goats were mated with Brucella-hee males. About three months later (at about mid-pregnancy), four ewes and four goats from each treatment group were sacrificed for bacteriological examination, together with all non-treated control animals.
Therapeutic agents
The pharmaceutical products employed in this study were: 
Treatment protocols
The treatment regimens of the six groups of infected sheep and goats are shown in Table I . ST was administered at the onset of therapy with OTC or LA-OTC. In group A, the daily dose of OTC (12 ml) was divided into two equal amounts (6 ml inoculated in the morning and 6 ml in the afternoon). The LA-OTC was administered i.m. in the cervical and the thigh regions.
Serological tests
Sera from all sheep and goats on the farms involved in the trial were initially screened for the presence of Brucella agglutinins by the Rose Bengal test (1) . The Rose Bengal test antigen was obtained from the Central Veterinary Laboratory, New Haw, Weybridge, United Kingdom. Sheep and goats found to be positive by the Rose Bengal test were retested by the standard US plate agglutination procedure (1) for the determination of Brucella antibody titres. In this procedure 0.08, 0.04, 0.02, 0.01 and 0.005 ml of serum were mixed with 0.03 ml of the standard Brucella plate antigen (made from B. abortus strain 1119-3 and obtained from the United States Department of Agriculture in Ames, Iowa, USA) and examined. When mixed with the antigen, these amounts of serum resulted in dilutions of 1:25, 1:50, 1:100, 1:200 and 1:400 respectively. Agglutinations at 1:50 or greater were considered positive.
Sera from the selected positive (serologically and bacteriologically) sheep and goats were tested before treatment and at bi-weekly intervals during and after treatment. Parallel serum samples were also collected and tested from the non-treated control animals until slaughter. In addition, sera from all lambs and kids born from treated animals were also tested.
Bacteriological examinations
In this study, the medium for Brucella culture was prepared from brain heart infusion agar to which 5% defibrinated sheep blood, 1 % sterile dextrose and Brucellaselective supplement were added (12) . The supplement was supplied in vials, each containing: The contents of each vial were dissolved in 10 ml of 50:50 mixture of methanol and sterile distilled water and added to each 500 ml of autoclaved medium (cooled at 50°C). The medium was then mixed well and poured into sterile Petri dishes.
Pre treatment cultures were prepared from udder secretions of all the treated and non-treated control animals to confirm shedding of B. melitensis from the selected serologically positive sheep and goats. Separate quarter samples (30 ml each) of the udder secretions were also cultured every week during treatment, every month from completion of treatments until lambing or kidding, and again every week after lambing or kidding until weaning time (about ten weeks later). In addition, repeated udder secretion samples from the 40 non-treated control animals were cultured every two weeks until sacrificed.
From the sacrificed treated and non-treated control animals, the following specimens were aseptically collected for bacteriological examination: udder secretions and/or udder tissues, supramammary, prescapular, iliac, precrural, mediastinal, mesenteric and head lymph nodes, sections of brain, uterus, ovary, liver and spleen, and bone marrow from the long bones of the front and hind limbs. In addition, samples of the stomach contents, liver, lung and spleen of foetuses from the sacrificed treated group of animals were cultured.
Each tissue specimen was individually homogenised in a tissue grinder and aliquots were spread with sterile cotton swabs on several (four to six) freshly prepared plates of culture medium. The plates were incubated at 37°C in the presence and absence of 5% CO 2 atmosphere for seven days. The isolated Brucella cultures were identified morphologically, microscopically, biochemically and serologically (1) . The biotyping of the identified isolates was carried out at the Central Veterinary Laboratory, New Haw, Weybridge, United Kingdom.
Sheep and goats in which B. melitensis could no longer be recovered from udder secretions nor from any of the selected tissue specimens collected at necropsy were considered cured (successful treatment). Animals which continued or resumed shedding B. melitensis in udder secretions, or in which Brucella organisms were isolated from any of the tissue specimens obtained at necropsy, were considered treatment failures.
In this study, aborted foetuses from the breeding farms involved were cultured for Brucella isolation in addition to the routine bacteriological examination for listeriosis, salmonellosis, mycoplasmosis and mycotic abortion.
RESULTS
Breeding performance
A comparison was made between the breeding performance in the breeding flocks involved before identification of the infected animals and in the treated animals in the breeding season following treatment. Before identification of the Brucella-infected animals, abortion rates in the breeding flocks involved ranged between 20% and 30%, and the infertility rate was approximately 35%. However, in the breeding season following treatment, about 96% of the treated animals were pregnant and had normal lambing or kidding with a high percentage of twins (the average number of offspring increased from 0.8 to 1.3). There were no premature parturitions among the treated animals. Data on the breeding performance of the infected non-treated control group of sheep and goats could not be obtained because these animals were not kept for breeding purposes.
Serological findings
All lambs and kids born from the treated ewes and female goats were found to be serologically negative for brucellosis. Before treatment, in both the treated and non-treated control animals, the agglutinin antibody titres ranged between 100 and 400 in the US plate agglutination test (218, 173 and 129 animals had titres of 100, 200 and 400 respectively).
At three months post-treatment, there was only a decrease of titre from 400 to 200 and from 200 to 100 in 80% of the 48 treated animals sacrificed. However, in the 40 non-treated control animals sacrificed there was an increase of titre from 100 to 200 and from 200 to 400 in 10% and 4% of the animals, respectively.
At eight months post-treatment, there was a further decrease of titres from 400 to 200, 200 to 100, 100 to 50 and from 50 to 25 in 38%, 31%, 22% and 9% of the remaining treated animals, respectively.
Cost of drugs and animals
The cost of antibiotics used was calculated according to prices on the Saudi market at the time of conducting the experiment (US$1 SR3.75). The cost of the antibiotics used to treat each individual animal in groups A, B, C, D, E and F was $447, $45, $18, $22, $17 and $13 respectively. This did not include the cost of interventions, because all laboratory examinations were made free of charge by governmental staff and the breeding farms involved had their own veterinary staff and supplies. Under different circumstances, the cost of interventions would have to be considered.
The treatment regimens used in this study did not show any harmful local or systemic side-effects on the health of the treated animals. In addition, meat inspection of the 48 treated animals slaughtered approximately three months after treatment revealed no detectable abnormalities in the muscles at the sites of repeated i.m. inoculation. Furthermore, since the studied animals were dried before initiation of treatment, no harmful effects were expected on human beings from antibiotic residues in the milk during and after treatment.
The price of a healthy adult Najdi ewe is between $160 and $320, and the price of a pure Syrian female goat ranges between $533 and $1,067 (or even higher as they are a very valuable breed which is imported to Saudi Arabia at highcosl)
In the present study, no listerias, salmonellas, mycoplasmas or pathogenic fungi were isolated from aborted foetuses on the breeding farms involved. Only B. melitensis biovar 2 was isolated. The efficacy of the six treatment regimens in eliminating B. melitensis in the 480 treated sheep and goats is shown in Table I .
The results of bacteriological examination for Brucella in the selected tissue specimens of the sacrificed treated animals (four sheep and four goats from each treatment group) and the non-treated control animals (20 sheep and 20 goats) are shown in Table II . All repeated udder secretion samples from the 72 non-sacrificed treated animals in each of groups A, B, D, E and F were free from Brucella (Table II) .
However, in group C, B. melitensis was isolated from udder tissues and secretions, supramammary lymph nodes and liver in one of the four sacrificed goats. In addition, the repeated udder secretion samples from three ewes and one goat of the 72 treated non-sacrificed animals were culture positive for B. melitensis. When these four positive animals (of regimen C) were treated again with the same regimen, they ceased shedding Brucella and their tissues were culture negative at necropsy three months after this second treatment.
All sacrificed non-treated control animals (20 ewes and 20 goats) were found to be culture positive. The rate of recovery of B. melitensis from the selected tissue specimens is shown in Table II . The average number of Brucella colonies recovered per plate from the specimens of control animals was about fifty times higher than from the udder secretions of the culture positive sheep and goats of group C (which ranged between one and three colonies per plate).
In all the successful treatments, shedding of Brucella in udder secretions ceased after one week from the initiation of therapy. However, in failed treatments (in group C) the amount of shedding declined after the onset of treatment and remained at a lower level until after termination of therapy.
DISCUSSION
In general, the treatment of animal brucellosis has not been fully successful because of the intercellular localisation of brucellas within phagocytic cells of the reticuloendothelial system in lymph nodes, liver, spleen, mammary glands and reproductive organs. Therefore, the brucellas are protected from antibodies, complement and antibiotics (6) . Other explanations for treatment failures include incorrect choice and dose of antibiotics or insufficient duration of treatment and/or improper routes of administration. In addition, the high cost of therapy, long duration of treatment, antibiotic residues in milk and meat and, in many cases, failure to cure udder infections have led to the general conclusion that treatment has no role in the control of animal brucellosis.
The recent use of OTC combined with ST gave promising results in curing cows infected with B. abortus (5, 13, 21, 22, 23) and sheep with B. melitensis (25) . OTC is a broad-spectrum antibiotic which is capable of intracellular penetration and inhibits bacterial protein synthesis at the level of the ribosomes. ST is also known to inhibit protein synthesis of Gram-negative bacteria. Furthermore, a synergistic effect has been demonstrated with OTC and ST in vivo and in vitro (22, 25, 27) . The LA-OTC was used to provide long-lasting OTC concentration in plasma. One injection of LA OTC gave effective OTC plasma concentration (0.6 /µg/ml) for three days (3). For these reasons, OTC or LA OTC combined with ST were selected for the treatment of sheep and goats naturally-infected with B. melitensis.
The present study indicates that long-term therapy and the combination of drugs resulted in a high level of efficacy among different regimens. This is in agreement with other studies on cows infected with B. abortus (21, 22) . In the present study, the inoculation of OTC (i.V.), LA OTC and ST (i.m.) did not give rise to local reactions or other harmful effects on the health of the treated sheep and goats.
The treated animals were considered cured when they remained asymptomatic and when no Brucella was isolated from the tissues or repeated udder secretion samples after termination of treatment. Cure by the combined action of OTC and ST as measured by the above parameters was clear. In humans, OTC has been considered the most effective antibiotic for treatment of brucellosis, although occasional relapses do occur. There have also been relapses in cows (15, 21, 22) . In the present study, the majority of the treated sheep and goats (90%) were retained for extended periods after termination of therapy and no relapse occurred in animals of groups A, B, D, E and F. However, relapses occurred in 6% of the treated animals in group C.
Although the treatment regimen in group A was safe and effective in eliminating B. melitensis, it was the most laborious and expensive. This was because highly purified, expensive OTC (intended for humans) was used, the number of i.v. injections was high and the method of administration required experienced staff.
The cost of antibiotics used for successful treatment of brucellosis in ewes and goats of group B was relatively high because the total dose of ST was high and required daily inoculation. Although the cost of antibiotics used in animals of group C was low and the regimen was practical, it was less effective in eliminating B.
melitensis.
Regardless of the source of antibiotics used in groups D and E, they were equally effective and successful in eliminating B. melitensis infection in 160 ewes and goats. On the other hand, the duration of treatment in groups D and E was relatively long (six weeks), and the dose of LA-OTC (28 mg/kg) and consequently the cost of drugs ($22 and $17 respectively) was fairly high.
The most practical, successful and least expensive regimen for eliminating B. melitensis from 80 naturally-infected sheep and goats was that used in group F. This regimen involved the administration of 25 mg/kg LA-OTC i.m. every 2 days for 4 weeks combined with 20 mg/kg ST i.m. every 2 days for 2 weeks.
Serology was of limited value in evaluating the effectiveness of the therapeutic regimens when monitored over a limited period of time (three and eight months). Other investigations revealed no reduction in agglutinating or complement fixing antibodies in treated cows from which Brucella was not isolated (13) .
Brucellosis in goats and sheep caused by B. melitensis is widespread in many areas of the world. The disease is responsible for serious economic losses in infected ñocks and constitutes a great hazard to public health. In campaigning against brucellosis, it is impossible to use a single method which would suit every country. A control campaign through slaughter and compensation is rarely within the financial capabilities of developing countries, especially where it is difficult to change agricultural customs or social habits. On the other hand, mass vaccination of infected flocks protects only non-infected animals without altering the course of infection, and the infected vaccinated animals remain a great hazard to public health.
Livestock producers in Saudi Arabia and many other developing countries cannot afford the traditional "test and slaughter" approach used in developed countries. In addition, slaughter of infected animals with superior genetic potential has serious economic and genetic consequences. Consequently, a practical and effective treatment regimen such as that used in group F in the present study would be a very useful alternative to slaughter of valuable infected animals.
In Saudi Arabia, the majority of breeding sheep and goats are imported at very high cost. The average wholesale prices per head of local and imported sheep and goats on the Saudi market are as follows (source given in brackets):
$72 (Australia) -$110 (Turkey) -$1,067 (Syria) -$300 (local pure Najdi ewe).
The average cost of antibiotics used in regimen F for treating a sheep or goat was $13, which represents between 1% and 21% of the original price of the animal. Such treatment costs are considered economically acceptable.
At the present time, treatment of brucellosis in sheep or goats using regimen F is recommended for valuable breeding animals. However, treatment at the flock level remains to be evaluated from the economic point of view. Furthermore, the treatment of seropositive animals should be accompanied by vaccination of all seronegative animals in the flock to achieve effective control and minimise the public health risk. 
